Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of BI 3000202 in Hepatic Impairment
NCT07486102Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- May 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 3000202 (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 to the last quantifiable data point up to 8 days and Maximum measured concentration up to 8 days. Started May 2026; status: recruiting.
02
Drugs
BI 3000202
Beyond the preview
Go deeper on NCT07486102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07486102.